HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pier Giorgio Natali Selected Research

ZD4054

4/2011Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
6/2010Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
2/2009Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
7/2007Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
7/2007ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
6/2006ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pier Giorgio Natali Research Topics

Disease

59Neoplasms (Cancer)
04/2021 - 07/2002
26Carcinoma (Carcinomatosis)
01/2012 - 07/2002
22Melanoma (Melanoma, Malignant)
11/2017 - 09/2002
14Ovarian Neoplasms (Ovarian Cancer)
12/2014 - 08/2002
12Breast Neoplasms (Breast Cancer)
07/2019 - 02/2004
9Carcinogenesis
06/2010 - 12/2005
8Neoplasm Metastasis (Metastasis)
07/2019 - 08/2002
5Hypoxia (Hypoxemia)
04/2014 - 08/2002
4Neuroblastoma
01/2012 - 08/2003
3Ovarian Epithelial Carcinoma
12/2014 - 06/2010
3Melanosis (Freckles)
03/2011 - 01/2009
3Sunburn
03/2011 - 01/2009
2Colonic Neoplasms (Colon Cancer)
07/2015 - 01/2008
2Colorectal Neoplasms (Colorectal Cancer)
07/2015 - 01/2008
2Adenocarcinoma
08/2013 - 08/2008
2Testicular Neoplasms (Testicular Cancer)
05/2008 - 04/2006
2Ascites
06/2006 - 08/2002
1Triple Negative Breast Neoplasms
02/2017

Drug/Important Bio-Agent (IBA)

24Endothelin-1 (Endothelin 1)IBA
04/2014 - 08/2002
16Proteins (Proteins, Gene)FDA Link
02/2017 - 08/2002
15Endothelin A ReceptorIBA
12/2014 - 11/2002
10LigandsIBA
04/2021 - 08/2003
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2014 - 08/2002
9Endothelins (Endothelin)IBA
04/2014 - 01/2004
9AtrasentanIBA
04/2006 - 08/2002
7Messenger RNA (mRNA)IBA
10/2010 - 08/2002
7AntigensIBA
09/2010 - 07/2002
6Epidermal Growth Factor (EGF)IBA
11/2017 - 03/2006
6AntibodiesIBA
04/2014 - 05/2004
6Peptides (Polypeptides)IBA
01/2014 - 05/2004
6ZD4054IBA
04/2011 - 06/2006
5Biomarkers (Surrogate Marker)IBA
07/2019 - 02/2004
5Endothelin Receptors (Endothelin Receptor)IBA
03/2013 - 08/2002
5ErbB Receptors (EGF Receptor)IBA
01/2010 - 11/2004
4Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
02/2007 - 07/2004
4ProstaglandinsIBA
02/2007 - 07/2004
4Complementary DNA (cDNA)IBA
06/2006 - 09/2002
4Peptide Hydrolases (Proteases)FDA Link
06/2006 - 08/2002
3Pharmaceutical PreparationsIBA
02/2017 - 04/2006
3Vascular Endothelial Growth Factor CIBA
04/2014 - 03/2009
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
03/2013 - 02/2009
3Cadherins (E-Cadherin)IBA
01/2012 - 11/2004
3Sunscreening Agents (Sunscreens)IBA
03/2011 - 01/2009
3VaccinesIBA
09/2010 - 01/2009
3MART-1 AntigenIBA
09/2010 - 01/2009
3Endothelin B ReceptorIBA
06/2010 - 02/2004
3Paclitaxel (Taxol)FDA LinkGeneric
06/2010 - 11/2004
3beta CateninIBA
02/2009 - 11/2004
3Mitogen-Activated Protein KinasesIBA
07/2007 - 11/2004
3Indicators and Reagents (Reagents)IBA
03/2006 - 09/2002
3Connexin 43 (Connexin43)IBA
11/2004 - 10/2003
2Immunoconjugates (Immunoconjugate)IBA
04/2021 - 11/2017
2Phenobarbital (Luminal)FDA Link
07/2019 - 01/2008
2CateninsIBA
07/2015 - 01/2012
2Small Interfering RNA (siRNA)IBA
04/2014 - 03/2009
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2014 - 08/2010
2Conditioned Culture MediaIBA
04/2014 - 01/2012
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2014 - 09/2011
2Biological ProductsIBA
05/2012 - 04/2006
2Dacarbazine (DIC)FDA LinkGeneric
09/2010 - 01/2009
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
09/2010 - 03/2009
2integrin-linked kinaseIBA
08/2010 - 04/2006
2beta-ArrestinsIBA
08/2010 - 02/2009
2taxaneIBA
06/2010 - 05/2003
2human ERBB2 proteinIBA
01/2010 - 03/2006
2Cancer VaccinesIBA
03/2009 - 01/2009
2Growth Factor ReceptorsIBA
02/2009 - 02/2007
2Protein Isoforms (Isoforms)IBA
08/2008 - 03/2007
2Caspase 3 (Caspase-3)IBA
07/2007 - 06/2006
2Progesterone Receptors (Progesterone Receptor)IBA
07/2007 - 03/2006
2DecitabineFDA Link
03/2007 - 04/2006
2Endothelin-3 (Endothelin 3)IBA
02/2007 - 11/2004
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2007 - 11/2004
2EnzymesIBA
01/2007 - 11/2004
2PolyphenolsIBA
06/2006 - 06/2006
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
06/2006 - 06/2006
2Tyrosine (L-Tyrosine)FDA Link
06/2006 - 10/2003
2TeaIBA
06/2006 - 06/2006
2Stem Cell FactorIBA
01/2005 - 08/2003
2Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA
01/2005 - 08/2003
2Dinoprostone (PGE2)FDA Link
11/2004 - 11/2004
2A 192621IBA
11/2004 - 02/2004
2Cyclooxygenase 1IBA
11/2004 - 07/2004
1Immune Checkpoint ProteinsIBA
01/2019
1Phosphotransferases (Kinase)IBA
11/2017
1Frizzled ReceptorsIBA
02/2017
1macitentanIBA
12/2014
1ArrestinIBA
12/2014
1HLA-C Antigens (HLA-C)IBA
01/2014
1HLA-G Antigens (HLA G)IBA
01/2014
1HLA-A Antigens (HLA-A)IBA
01/2014
1HLA-B Antigens (HLA-B)IBA
01/2014
1Formaldehyde (Formol)FDA Link
08/2013
1ParaffinIBA
08/2013
1MicroRNAs (MicroRNA)IBA
08/2013
1Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
03/2013

Therapy/Procedure

16Therapeutics
04/2021 - 11/2002
7Immunotherapy
01/2019 - 04/2006
5Drug Therapy (Chemotherapy)
12/2014 - 02/2004
1Adjuvant Chemotherapy
03/2013